Use of anti-TNFs for difficult-to-treat urticaria: response to Cooke et al

Simon Francis Thomsen,^1,2 Freja Lærke Sand<sup>1,2

1</sup>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark; ²Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

We read with interest the recent paper by Cooke et al about the use of biologic agents for intractable urticaria.¹ Particularly, the authors reckon that the evidence supporting the use of anti-TNFs is limited by the small numbers of patients in non-controlled studies, often with urticarial disorders not typical of chronic urticaria such as vasculitis and delayed pressure urticaria. However, we want to draw the authors’ and readers’ attention to our report from 2013 about the use of adalimumab and etanercept in 20 patients with chronic urticaria with or without angioedema² (updated in 2015 with an additional five patients).³


View original article by Cooke et al 

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.